UBS Group’s BioRestorative Therapies BRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BRTX
HF
XT
WA
KFGK
UBS Group's BRTX Position: Q2 2026 in Review
UBS Group reduced its BioRestorative Therapies (BRTX) stake by 100% in Q2 2026, selling an estimated $29.2K and leaving 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #10474.
UBS Group first reported a position in BRTX in Q4 2021 and has held it in 17 quarters since. The position peaked at $56.5K in Q2 2024. 21 funds tracked by Wall St. Rank hold BRTX as of Q2 2026.
- UBS Group held 1 share of BioRestorative Therapies worth $0 as of Q2 2026.
- UBS Group sold 99,831 BioRestorative Therapies shares in Q2 2026, an estimated $29.2K.
- BioRestorative Therapies made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10474 holding.
- UBS Group first reported a position in BioRestorative Therapies in Q4 2021 and has held it in 17 quarters since.
- UBS Group's BioRestorative Therapies position peaked at $56.5K in Q2 2024.
- 21 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.